Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

We live in an era when many sectors are dynamic, and one of the many that’s quite active in the past several years is the ...

Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

Discover the best sectors for growth stocks in the next decade. Explore which sectors may present an opportunity to bolster ...

Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

A groundbreaking $50 million investment has been announced to combat the growing threat of antimicrobial resistance (AMR) in ...

Research into developing new antimicrobial resistance treatment in Nigeria and other low/middle-income countries has fuelled ...

Research into developing new antimicrobial resistance treatments in Nigeria and other low/middle-income countries has secured ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Melio Bio, a biotech dedicated to the discovery and development of novel inhibitors targeting a receptor implicated in obesity and associated co-morbidities, has been revealed as the winner of Pioneer ...

Debate over childhood obesity treatments: weight-loss drugs vs. lifestyle changes, with concerns about long-term effects.